Symbol
| PDE11A
| contributors: mct/pgu - updated : 18-12-2018
|
HGNC name
| phosphodiesterase 11A
|
HGNC id
| 8773
|
corresponding disease(s)
|
PPNAD2
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
| LOH
|  
| loss of function
|
of PDE11A4 in adrenocortical hyperplasia and Cushing syndrome, and patients with micronodular adrenocortical hyperplasia  | constitutional
|  
|  
|  
| loss of function
|
in bilateral adrenocortical hyperplasia (BAH) | |
Susceptibility
|
to acromegaly to prostatic cancer |
Variant & Polymorphism
other
| variants in a subset of acromegalic patients, which was only slightly more frequent than in control (variants might only marginally contribute to the development of somatotropinomas)  |
|
PDE11A-inactivating genetic alterations may play a role in susceptibility to prostatic cancer  |
|
|
|
|
Candidate gene
Marker
Therapy target
| | | |
| PDE11A KO mice exhibit several subtle psychiatric-disease–related phenotypes indicative of ventral hippocampus dysfunction  |